Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada.
COVID-19
hospitalization
intensive care unit
phylogeny
variant of concern
whole genome sequencing
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
11
11
2022
received:
08
07
2022
accepted:
05
12
2022
pubmed:
23
12
2022
medline:
11
1
2023
entrez:
22
12
2022
Statut:
ppublish
Résumé
The SARS-CoV-2 variant Omicron emerged in late 2021. In British Columbia (BC), Canada, and globally, three genetically distinct subvariants of Omicron, BA.1, BA.2, and BA.5, emerged and became dominant successively within an 8-month period. SARS-CoV-2 subvariants continue to circulate in the population, acquiring new mutations that have the potential to alter infectivity, immunity, and disease severity. Here, we report a propensity-matched severity analysis from residents of BC over the course of the Omicron wave, including 39,237 individuals infected with BA.1, BA.2, or BA.5 based on paired high-quality sequence data and linked to comprehensive clinical outcomes data between December 23, 2021 and August 31, 2022. Relative to BA.1, BA.2 cases were associated with a 15% and 28% lower risk of hospitalization and intensive care unit (ICU) admission (aHR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28423Subventions
Organisme : CIHR
Pays : Canada
Organisme : CIHR
ID : GA1-177697
Pays : Canada
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature. 2022;603:679-686.
Fonager J, Bennedbaek M, Bager P, et al. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Eurosurveill. 2022;27(10):2200181. doi:10.2807/1560-7917.ES.2022.27.10.2200181
Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28:1785-1790.
Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422-2433.e13.
Wolter N, Jassat W, Walaza S, et al. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat Comm. 2022;13:5860.
Relova S, Joffres Y, Rasali D, Zhang LR, McKee G, Janjua N. British Columbia's index of multiple deprivation for community health service areas. Data. 2022;7:24.
Wolter N, Jassat W, DATCOV-Gen. Clinical Severity of Omicron Sub-Lineage BA.2 Compared to BA.1 in South Africa, 2022. http://medrxiv.org/lookup/doi/10.1101/.02.17.22271030.
UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants Under Investigation in England - Technical Briefing 37.GOV.UK; 2022.
Webster HH, Nyberg T, Sinnathamby MA, et al. Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. Nat Comm. 2022;13:6053.
Kouamen A-C, Da Cruz H, Hamidouche M, et al. Rapid investigation of BA.4/BA.5 cases in France. Front Public Health. 2022;10:1006631.
Hansen CH, Friis NU, Bager P, et al. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark. Lancet Infect Dis. 2022;S1473-3099(22):00595-3. doi:10.1016/S1473-3099(22)00595-3
Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Comm, 13:3082.
Davies M-A, Morden E, Rosseau p, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by OmicronOmicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province. MedRxiv.
Harrigan SP, Wilton J, Chong M, et al. Clinical severity of Omicron SARS-CoV-2 variant relative to Delta in British Columbia, Canada: a retrospective analysis of whole genome sequenced cases. Clin Infect Dis. 2022:ciac705. doi:10.1093/cid/ciac705